Carisma Therapeutics has increased its series B round to $59m thanks to an extension backed by IP Group, Penn Medicine and 4Bio Capital.
Carisma Therapeutics, a US-based cancer immunotherapy spinout of University of Pennsylvania, grew its series B round to $59m yesterday following a $12m extension backed by commercialisation firm IP Group.
Penn Medicine, which consists of the institution’s Perelman School of Medicine and medical care provider University of Pennsylvania Health System, also backed the second tranche, as did venture capital firm 4Bio Capital.
Carisma picked up an initial $47m in series B funding in January 2021 that also featured…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
